# US Zika Virus Testing Market

> US Zika Virus Testing Market Research Report: Size, Share, Trend Analysis By Tests Include (serological/Zika virus antibody, molecular/nucleic acid amplification) and By End-Users (Diagnostic units, hospitals, pathology labs) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.84%
- **2024:** $ 31.5 Million
- **2025:** $ 33.65 Million
- **2035:** $ 65.2 Million
- **Key Players:** Abbott Laboratories (US), Roche Diagnostics (CH), Thermo Fisher Scientific (US), Siemens Healthineers (DE), Bio-Rad Laboratories (US), Cepheid (US), Hologic (US), Quidel Corporation (US)

**Report ID:** MRFR/LS/18552-HCR · **Pages:** 100 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-zika-virus-testing-market-20099

---

## Market Summary

## **US Zika Virus Testing Market Overview**

As per MRFR analysis, the US Zika Virus Testing Market Size was estimated at 27.72 (USD Million) in 2023. The US Zika Virus Testing Market Industry is expected to grow from 31.5(USD Million) in 2024 to 65 (USD Million) by 2035. The US Zika Virus Testing Market CAGR (growth rate) is expected to be around 6.807% during the forecast period (2025 - 2035).

### **Key US Zika Virus Testing Market Trends Highlighted**

In the US Zika Virus Testing Market, an increase in awareness and preparedness against mosquito-borne diseases is driving the demand for testing. Following outbreaks, health authorities have amplified campaigns to educate the public on Zika virus transmission and its health implications. This heightened awareness is pushing both healthcare providers and consumers to seek better testing solutions, thus propelling market growth.

The growing trend of home testing kits is also emerging, offering convenience and quick results, which appeals to individuals concerned about the virus, especially during peak mosquito season. Opportunities in the market mainly lie in advancing diagnostic technologies.The continuous evolution in molecular testing techniques presents a chance for firms to incorporate faster and more accurate testing methods.

This is particularly significant in the US, where the CDC emphasizes the importance of rapid and reliable Zika diagnostics to manage outbreaks effectively. Additionally, collaborations between public health agencies and private companies could create seamless integration of testing services, providing broader access to populations at risk. Recent trends show a shift toward integrating Zika testing with other vector-borne disease tests, making it part of a comprehensive diagnostic approach.

As the US faces potential future outbreaks, there is a growing emphasis on developing multiplex tests that can screen for multiple infections simultaneously.This trend reflects the need for healthcare systems to operate more efficiently and respond swiftly to emerging public health threats. Overall, the focus on enhancing testing capabilities and accessibility highlights a proactive strategy in the US public health landscape.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **US Zika Virus Testing Market Drivers**

#### **Increasing Awareness of Zika Virus Transmission and Effects**

The rising awareness about Zika Virus and its transmission is a significant driver for the US Zika Virus Testing Market Industry. Public health organizations like the Centers for Disease Control and Prevention (CDC) have highlighted the risks associated with Zika Virus, particularly its potential to cause severe birth defects such as microcephaly in infants when pregnant women are infected.

According to the CDC, approximately 1 in 10 infants in the US may be born with Zika-related birth defects if the mother is infected during pregnancy.This alarming statistic is raising awareness and prompting pregnant women to seek testing, thus contributing to market growth. Furthermore, educational campaigns have been implemented to inform the public on protecting themselves from mosquito bites, which serves to underline the importance of testing for Zika Virus and drives more individuals towards getting tested.

#### **Advancements in Diagnostic Technology**

Technological advancements in diagnostic testing for Zika Virus are a critical driver for the US [Zika Virus Testing Market](../../../reports/zika-virus-testing-market-5662) Industry. Innovations such as polymerase chain reaction (PCR) tests have significantly improved the speed and accuracy of diagnosing Zika Virus infections. According to the FDA, recent approvals of rapid test kits have made it easier and faster for healthcare providers to conduct Zika testing.

These advancements not only enhance detection rates but also reduce the time it takes for individuals to receive their results, thereby encouraging more people to undergo testing as they can have peace of mind more quickly.Such technological developments are supported by various established organizations in the healthcare sector that are investing in Research and Development to enhance testing methodologies.

#### **Government Policies and Funding for Vector Control and Surveillance**

Government policies aimed at improving vector control efforts can significantly influence the US Zika Virus Testing Market Industry. The United States Department of Health and Human Services has allocated substantial funding for vector control programs to mitigate the spread of Zika Virus through mosquito populations. For instance, a report from the US Congress states that approximately 20 million USD is periodically dedicated to support vector control activities aimed at preventing mosquito-borne diseases, including Zika Virus.

These initiatives not only reduce transmission but also promote the significance of testing, leading to increased demand within the testing market as communities are more aware of potential Zika virus exposure.

### **US Zika Virus Testing Market Segment Insights**

#### **Zika Virus Testing Market Tests Include Insights**

The US Zika Virus Testing Market demonstrates a growing focus on various testing methodologies, particularly in the Tests Include segment, which comprises diverse options such as serological testing, specifically Zika virus antibody tests, and molecular testing, including nucleic acid amplification techniques. Serological testing plays a critical role in identifying past infections through the detection of specific antibodies in the bloodstream, crucial for understanding population immunity and exposure levels.

This method is particularly significant due to its practical applications in epidemiological studies, where broad screening can inform public health responses to outbreaks.On the other hand, molecular testing methods like nucleic acid amplification are vital for diagnosing active infections, offering high sensitivity and specificity. This type of testing is increasingly preferred in clinical settings because it enables timely intervention and management of affected individuals, contributing to decreased transmission rates.

Overall, the increasing prevalence of Zika virus cases and heightened awareness of vector-borne diseases drive innovations and advancements in testing techniques, necessitating continual investment in Research and Development.This evolving landscape presents both challenges and opportunities as healthcare providers and researchers strive to enhance diagnostic capabilities against the Zika virus, ultimately aiming to improve health outcomes for affected populations in the US.

As public health initiatives underscore the necessity for effective surveillance and rapid response strategies, the importance of these testing methods will undoubtedly continue to strengthen, aiding in the effort to control and prevent Zika virus transmission within the nation.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

#### **Zika Virus Testing Market End-Users Insights**

The US Zika Virus Testing Market is comprised of various End-Users, including diagnostic units, hospitals, and pathology labs, which play vital roles in the effective detection and management of the Zika virus. Diagnostic units facilitate rapid testing and are essential in outbreak response and monitoring, ensuring timely identification of infected individuals. Hospitals serve as critical points for patient care, providing comprehensive healthcare services and facilitating testing for Zika virus alongside other infectious diseases.

Pathology labs are crucial for conducting detailed analyses and confirmatory tests, which support accurate diagnosis and appropriate patient management.Increasing awareness of Zika virus transmission and associated health risks drives demand across these End-User segments. Additionally, government initiatives and funding aim to bolster testing capabilities in response to healthcare needs, indicating significant growth opportunities within this market.

The interplay between these End-Users enhances the overall US Zika Virus Testing Market data, ensuring robust responses during outbreaks and contributing to public health safety. With advances in technology and testing methodologies, these segments are poised to adapt and respond effectively to the evolving landscape of viral testing and disease management in the US.

### **US Zika Virus Testing Market Key Players and Competitive Insights**

The US Zika Virus Testing Market has seen significant developments since the virus's emergence, characterized by a series of competitive dynamics among prominent players in the healthcare diagnostic sector. The market landscape is shaped by the rising demand for efficient and rapid testing methods to address the public health concerns associated with Zika virus transmission. Competitive insights reveal a focus on innovation, regulatory compliance, and strategic partnerships among market participants.

Companies are striving to enhance their product portfolios and expand their geographic reach through initiatives that ensure comprehensive testing solutions. This climate is further influenced by factors such as government policies, health awareness campaigns, and the increasing incidence of vector-borne diseases, all of which drive innovation in testing technologies and services.

Hologic is recognized for its strong presence in the US Zika Virus Testing Market, where it leverages its expertise in molecular diagnostics. The company has established a reputation for delivering reliable and accurate testing solutions that are vital in the fight against the Zika virus. Hologic's strengths lie in its advanced technologies, consistent product innovation, and commitment to patient safety and accuracy. Its testing platforms contribute significantly to the detection and management of Zika virus infections.

The company's focus on research and collaboration with various health organizations ensures its offerings are aligned with current healthcare needs, helping to maintain its competitive edge within the market.LabCorp is another key player in the US Zika Virus Testing Market, providing an extensive array of diagnostic services, with a strong focus on infectious disease testing. The company offers a wide range of testing solutions, including serological and molecular tests specifically designed for Zika virus detection.

LabCorp's market presence is bolstered by its large network of laboratories and extensive distribution channels, which enable timely access to testing services across the nation. Furthermore, LabCorp's strategy includes continuous investment in technological upgrades and collaborations aimed at enhancing its testing capabilities. The company's ability to integrate various diagnostic services and streamline operations strengthens its position within the Zika virus testing market, making it a trusted partner for healthcare providers and patients alike.

Mergers and acquisitions also play a pivotal role in LabCorp's growth strategy, allowing the company to expand its service offerings and improve its capabilities in a rapidly evolving healthcare landscape.

### **Key Companies in the US Zika Virus Testing Market Include**

### **US Zika Virus Testing Market Industry Developments**

The US Zika Virus Testing Market has seen notable developments, particularly due to increased awareness of arboviral diseases. In March 2023, Hologic introduced an innovative molecular diagnostic test enhancing the speed of detection for Zika and other pathogens, improving patient outcomes and efficiency in healthcare settings. LabCorp and Quest Diagnostics have expanded their testing capabilities to meet rising demands, especially as Zika virus concerns intertwined with other mosquito-borne viruses like West Nile and dengue.

The valuation of the market is also boosted by strategic investments in Research and Development by companies such as Roche Diagnostics and Abbott Laboratories. In May 2023, Meridian Bioscience announced a collaboration with Cepheid to enhance Zika virus testing efficiency further. Notably, in January 2022, Genetic Engineering Institute expanded its product line to include serological tests for Zika virus, showcasing a commitment to addressing emerging health threats.

As public health agencies continue to monitor Zika transmission pathways, the market is likely to grow, driven by the participation of organizations like BioReference Laboratories and Alere in research initiatives focused on new testing methodologies.

### **US Zika Virus Testing Market Segmentation Insights**

#### **Zika Virus Testing Market Tests Include Outlook**

#### **Zika Virus Testing Market End-Users Outlook**

## Market Drivers

### Increased Focus on Vector Control

The zika virus-testing market is also driven by an increased focus on vector control measures. As the primary mode of transmission for the zika virus is through mosquito bites, public health campaigns aimed at controlling mosquito populations have become more prevalent. This heightened focus on vector control has led to a corresponding increase in the demand for testing, as effective control measures require accurate data on zika virus prevalence. The market is likely to see growth as health authorities emphasize the importance of testing in conjunction with vector control strategies, ensuring that the zika virus-testing market remains relevant in public health discussions.

### Government Initiatives and Funding

Government initiatives and funding play a crucial role in shaping the zika virus-testing market. Federal and state health agencies are allocating resources to combat the zika virus, which includes funding for research and development of testing methods. For instance, the National Institutes of Health (NIH) has invested millions in zika virus research, which indirectly supports the testing market by fostering innovation. This financial backing is likely to stimulate the development of new testing technologies and improve existing ones, thereby expanding the zika virus-testing market. As public health priorities shift towards infectious disease management, the market is poised for growth.

### Rising Incidence of Zika Virus Cases

The zika virus-testing market is experiencing growth due to the rising incidence of zika virus cases in the US. As the number of reported cases increases, healthcare providers are more likely to recommend testing, thereby driving demand for testing services and products. According to the Centers for Disease Control and Prevention (CDC), there were approximately 1,000 reported cases of zika virus in the US in recent years, highlighting the need for effective testing solutions. This trend suggests that as awareness of zika virus transmission rises, the zika virus-testing market will likely expand to meet the growing healthcare needs of the population.

### Advancements in Diagnostic Technologies

The zika virus-testing market is significantly influenced by advancements in diagnostic technologies. Innovations such as polymerase chain reaction (PCR) testing and serological assays have improved the accuracy and speed of zika virus detection. These technological advancements not only enhance the reliability of test results but also reduce the time required for diagnosis, which is crucial for effective patient management. The market for diagnostic testing is projected to reach $1 billion by 2026, indicating a robust growth trajectory. As healthcare providers increasingly adopt these advanced testing methods, the zika virus-testing market is expected to benefit from enhanced testing capabilities.

### Rising Demand for Preventive Healthcare

The zika virus-testing market benefits from a rising demand for preventive healthcare measures. As individuals become more health-conscious, there is a growing inclination towards early detection and prevention of diseases, including those caused by the zika virus. This trend is reflected in the increasing number of people seeking testing services, particularly in areas where zika virus transmission is a concern. The preventive healthcare market is projected to grow at a CAGR of 7% over the next five years, indicating a favorable environment for the zika virus-testing market. As awareness of preventive measures continues to rise, the market is likely to expand to accommodate this shift in consumer behavior.

## Future Outlook

The [Zika Virus Testing Market](https://www.marketresearchfuture.com/reports/zika-virus-testing-market-5662) is projected to grow at a 6.84% CAGR from 2025 to 2035, driven by technological advancements, increased awareness, and rising healthcare investments.

**New opportunities:**

- Development of rapid testing kits for remote areas Integration of AI for predictive analytics in testing Expansion of telehealth services for zika testing consultations

By 2035, the zika virus-testing market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Test Type: Serological/Zika virus antibody (Largest) vs. Molecular/Nucleic acid amplification (Fastest-Growing)

In the US zika virus-testing market, the Serological/Zika virus antibody segment holds a significant share, reflecting its established role in diagnosing past infections through antibody detection. This method's widespread acceptance and reliability contribute to its dominant position, making it the preferred choice among healthcare providers.

Conversely, the Molecular/Nucleic acid amplification segment is rapidly gaining traction, driven by the increasing demand for accurate and timely results in acute infections. Innovations in testing technologies and a surge in research funding to combat infectious diseases fuel its growth trajectory, positioning it as the fastest-growing segment in the market.

Test Type: Serological/Zika virus antibody (Dominant) vs. Molecular/Nucleic acid amplification (Emerging)

The Serological/Zika virus antibody testing method is characterized by its ability to detect immune responses to the virus, making it invaluable for retrospective studies and epidemiological tracking. It is widely implemented in public health frameworks, benefiting from established protocols and infrastructure. On the other hand, the Molecular/Nucleic acid amplification segment represents an emerging technology that offers rapid and accurate detection of viral RNA, meeting the needs of healthcare settings for timely intervention. This segment's innovation potential and alignment with modern healthcare demands position it as a key player, further driving advancements in the US zika virus-testing market.

### By End-User: Diagnostic units (Largest) vs. Hospitals (Fastest-Growing)

In the US zika virus-testing market, the end-user segment reveals significant distribution among diagnostic units, hospitals, and pathology labs. Diagnostic units hold the largest share, as they are primarily responsible for rapid testing and immediate results. Hospitals are seeing growing adoption, driven by increased patient volumes and the integration of advanced testing technologies. Pathology labs play a supportive role but maintain a smaller part of market share compared to the other two segments.

The growth trends in this segment are influenced by the rising awareness of zika virus testing along with a surge in healthcare initiatives aimed at combating mosquito-borne diseases. Hospitals are emerging as the fastest-growing segment due to improved healthcare access and funding for enhanced laboratory capabilities. Diagnostic units will continue to dominate, serving a crucial role in initial testing, while hospitals are expected to expand their testing services to accommodate the growing demand.

Diagnostic units (Dominant) vs. Hospitals (Emerging)

Diagnostic units are characterized by their ability to deliver quick and accurate zika virus testing, representing the dominant force in the US zika virus-testing market. They focus on emerging technologies and point-of-care testing, making them integral in early detection efforts. Meanwhile, hospitals, while still emerging in their testing approaches, are increasingly adopting sophisticated diagnostic tools and expanding their laboratory capabilities to meet rising patient demands. This growth is fueled by investments in healthcare infrastructure and an increase in patient awareness, which encourages hospitals to enhance their testing services to remain competitive in the market.

## Competitive Benchmarking

The zika virus-testing market is characterized by a competitive landscape that is increasingly shaped by innovation, strategic partnerships, and a focus on regional expansion. Key players such as Abbott Laboratories (US), Roche Diagnostics (CH), and Thermo Fisher Scientific (US) are at the forefront, leveraging their technological capabilities to enhance testing accuracy and efficiency. Abbott Laboratories (US) has positioned itself as a leader in rapid testing solutions, while Roche Diagnostics (CH) emphasizes its commitment to research and development, aiming to introduce next-generation testing methodologies. Thermo Fisher Scientific (US) focuses on integrating advanced analytics into its testing platforms, thereby enhancing the overall user experience and operational efficiency. Collectively, these strategies contribute to a dynamic competitive environment, where companies are not only vying for market share but also striving to set new standards in testing reliability and speed.In terms of business tactics, companies are increasingly localizing manufacturing to reduce lead times and optimize supply chains. This approach appears to be a response to the growing demand for rapid testing solutions, particularly in regions prone to zika outbreaks. The market structure is moderately fragmented, with several players competing for dominance. However, the influence of major companies is substantial, as they often set the benchmarks for quality and innovation that smaller firms strive to meet.
In October Roche Diagnostics (CH) announced a strategic partnership with a leading biotechnology firm to co-develop a novel zika virus testing platform that utilizes next-generation sequencing technology. This collaboration is expected to enhance the sensitivity and specificity of zika testing, potentially revolutionizing the diagnostic landscape. The strategic importance of this partnership lies in its potential to position Roche as a pioneer in advanced testing methodologies, thereby strengthening its market position.
In September Abbott Laboratories (US) launched a new rapid zika virus test that promises results in under 30 minutes. This innovation is particularly significant as it addresses the urgent need for timely diagnosis in outbreak scenarios. By prioritizing speed and accuracy, Abbott aims to capture a larger share of the market, appealing to healthcare providers who require efficient testing solutions.
In August Thermo Fisher Scientific (US) expanded its product portfolio by introducing a comprehensive zika virus testing kit that integrates AI-driven analytics. This move not only enhances the testing process but also provides healthcare professionals with actionable insights, thereby improving patient outcomes. The integration of AI signifies a broader trend towards digitalization in the testing market, reflecting the growing importance of technology in healthcare.
As of November current competitive trends indicate a shift towards digitalization, sustainability, and the integration of AI technologies. Strategic alliances are increasingly shaping the landscape, allowing companies to pool resources and expertise to drive innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological advancements, innovation, and supply chain reliability. This transition underscores the importance of agility and responsiveness in meeting the evolving needs of the market.

## Recent News & Developments

The US Zika Virus Testing Market has seen notable developments, particularly due to increased awareness of arboviral diseases. In March 2023, Hologic introduced an innovative molecular diagnostic test enhancing the speed of detection for Zika and other pathogens, improving patient outcomes and efficiency in healthcare settings. LabCorp and Quest Diagnostics have expanded their testing capabilities to meet rising demands, especially as Zika virus concerns intertwined with other mosquito-borne viruses like West Nile and dengue.

The valuation of the market is also boosted by strategic investments in Research and Development by companies such as Roche Diagnostics and Abbott Laboratories. In May 2023, Meridian Bioscience announced a collaboration with Cepheid to enhance Zika virus testing efficiency further. Notably, in January 2022, Genetic Engineering Institute expanded its product line to include serological tests for Zika virus, showcasing a commitment to addressing emerging health threats.

As public health agencies continue to monitor Zika transmission pathways, the market is likely to grow, driven by the participation of organizations like BioReference Laboratories and Alere in research initiatives focused on new testing methodologies.

## Report Scope

| MARKET SIZE 2024 | 31.5(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 33.65(USD Million) |
| MARKET SIZE 2035 | 65.2(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.84% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Abbott Laboratories (US), Roche Diagnostics (CH), Thermo Fisher Scientific (US), Siemens Healthineers (DE), Bio-Rad Laboratories (US), Cepheid (US), Hologic (US), Quidel Corporation (US) |
| Segments Covered | Test Type, End-User |
| Key Market Opportunities | Advancements in rapid diagnostic technologies enhance accessibility in the zika virus-testing market. |
| Key Market Dynamics | Regulatory changes and technological advancements drive innovation in the zika virus-testing market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the market valuation of the US zika virus-testing market in 2024?**
A: The market valuation was $31.5 Million in 2024.

**Q: What is the projected market valuation for the US zika virus-testing market in 2035?**
A: The projected valuation for 2035 is $65.2 Million.

**Q: What is the expected CAGR for the US zika virus-testing market during the forecast period 2025 - 2035?**
A: The expected CAGR is 6.84% during the forecast period 2025 - 2035.

**Q: Which companies are considered key players in the US zika virus-testing market?**
A: Key players include Abbott Laboratories, Roche Diagnostics, Thermo Fisher Scientific, Siemens Healthineers, Bio-Rad Laboratories, Cepheid, Hologic, and Quidel Corporation.

**Q: What are the two main test types in the US zika virus-testing market and their valuations?**
A: The two main test types are Serological/Zika virus antibody, valued at $25.0 Million, and Molecular/Nucleic acid amplification, valued at $40.2 Million.

**Q: How do diagnostic units and hospitals contribute to the US zika virus-testing market?**
A: Diagnostic units contributed $21.0 Million and hospitals contributed $25.0 Million to the market.

**Q: What is the valuation of pathology labs in the US zika virus-testing market?**
A: Pathology labs had a valuation of $19.2 Million in the market.

**Q: How does the market for serological tests compare to molecular tests in terms of valuation?**
A: Serological tests are valued at $25.0 Million, while molecular tests are valued higher at $40.2 Million.

**Q: What trends are expected in the US zika virus-testing market by 2035?**
A: The market is expected to grow, reaching a valuation of $65.2 Million by 2035, indicating a robust demand for testing.

**Q: What factors might influence the growth of the US zika virus-testing market in the coming years?**
A: Factors such as advancements in testing technology and increased awareness of zika virus risks may influence market growth.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-zika-virus-testing-market-20099*